Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis

• DOI: 10.1038/s41385-019-0148-2
• Publication Date: 2019-02-18T12:05:46Z
• Authors: Juan I. Moliva; Austin P. Hossfeld; Sabeen Sidiki; Cynthia H. Canan; Varun Dwivedi; Gillian Beamer; Joanne Turner; Jordi B. Torrelles
• Keywords: 0301 basic medicine; Interleukin-17; Vaccination; Mycobacterium tuberculosis; Lipid Metabolism; Lipids; Mycobacterium bovis; Article; 3. Good health; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Alkanes; BCG Vaccine; Animals; Female; Inflammation Mediators; Lung; Tuberculosis, Pulmonary

Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB), is the leading killer due to an infectious organism. Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only vaccine approved against TB, however, its efficacy against pulmonary TB is poor. While BCG is currently inoculated intradermally, the natural route of M.tb infection is through the lung. Excessive lung pathology caused by pulmonary inoculation of BCG has prevented the use of this immunization route. Here, we show that selective chemical treatment of BCG with petroleum ether removes inflammatory lipids from the bacterial surface while keeping BCG viable. Pulmonary vaccination using this modified BCG attenuated inflammatory responses, prevented immunopathology of the lung, and significantly increased protection against M.tb infection in mice. We further directly linked IL-17A as the responsible contributor of improved immunity against M.tb infection. These results provide evidence that selective removal of cytotoxic lipids from the BCG surface attenuates inflammation and offers a safer and superior vaccine against TB causing less damage post-infectious challenge with M.tb.